Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809596 · ClinicalTrials.gov registry record · NA
HEAL-LAA Clinical Trial
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 949
- Enrollment target
NCT05809596 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 949 participants.
The verdict
NCT05809596, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 949 participants
- Enrollment target
Study Summary
The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
Interventions
- DEVICE WATCHMAN FLX Pro LAAC Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2025-09-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05809596
The ClinicalTrials.gov registry entry for NCT05809596 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 949 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WATCHMAN FLX Pro LAAC Device is the first listed.
NCT05809596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05809596 about?
NCT05809596 is a clinical study titled "HEAL-LAA Clinical Trial". The primary objective of this study is to collect real-world data on WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device in patients with non-valvular atrial fibrillation.
What is the current status of trial NCT05809596?
This trial is currently completed. It is a NA study. The enrollment target is 949 participants. The study started on 2023-10-03. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT05809596?
The interventions under investigation include: WATCHMAN FLX Pro LAAC Device (DEVICE).
Who is sponsoring clinical trial NCT05809596?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.